生物制剂部分缓解银屑病患者共病对全因死亡率的负面影响:一项真实世界病例对照研究
该研究基于加拿大阿尔伯塔省2012至2019年数据库,纳入18,618例银屑病患者及按年龄性别1:3匹配的对照,评估共病与治疗对死亡率的影响。银屑病队列死亡率显著高于对照(中位死亡年龄72.0岁 vs 74.4岁),生物制剂治疗与较低死亡率相关(HR 0.54)。
要点
- 药源性肝损伤、双相情感障碍和主要心血管疾病是死亡的强预测因素。
- 生物制剂治疗与死亡率降低相关(HR 0.54)。
核心结论
- 肝损伤、精神情感障碍和心血管疾病是银屑病患者总体生存的主要决定因素。
- 生物制剂治疗与银屑病患者死亡风险降低相关。
研究设计与样本
- 银屑病病例18,618例,对照为门诊患者按年龄和性别1:3匹配。
- 病例按Charlson共病指数和治疗类型分层。
主要发现
- 银屑病队列死亡率显著高于对照,中位死亡年龄72.0岁 vs 74.4岁。
- Charlson共病指数及共病是死亡率的强预测因素。
- 药源性肝损伤风险比1.8,双相情感障碍风险比1.6,主要心血管疾病亦为强预测因素。
- 生物制剂治疗者死亡率较低,风险比0.54。
临床怎么用
- 对银屑病患者应重视共病筛查与管理,尤其是肝损伤、精神情感障碍和心血管疾病。
- 生物制剂治疗可能有助于改善银屑病患者总体生存。
局限性
- 无法测量银屑病类型和严重程度、治疗反应、吸烟及饮酒等因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiovascular comorbidities are believed to cause higher mortality in psoriasis patients. Conversely, systemic therapy may improve overall survival. OBJECTIVE: To evaluate the impact of different comorbidities and therapy on mortality risk of psoriasis patients in the entire population of Alberta, Canada (population 4.37 million). METHODS: Cohorts of psoriasis cases (n = 18,618) and controls (ambulatory patients matched 1:3 by age and sex) were retrieved from Alberta Health Services Data Repository of Reporting database within the period 2012 to 2019. Cases were stratified according to Charlson Comorbidity Index, and the type of therapy. RESULTS: Mortality in psoriasis cohort was significantly higher than in the controls (median age of death 72.0 years vs 74.4 years, respectively). Charlson Comorbidity Index and comorbidities were strong predictors of mortality, in particular drug induced liver injury (hazard ratio 1.8, affective bipolar disease, hazard ratio 1.6, and major cardiovascular diseases. Mortality was lower in patients treated with biologics (hazard ratio 0.54). LIMITATIONS: Some factors (psoriasis type and severity, response to treatment, smoking, alcohol intake) could not be measured. CONCLUSIONS: Hepatic injury, psychiatric affective disorders and cardiovascular disease were major determinants of overall survival in psoriasis. Biologic therapy was associated with a reduced mortality risk.
引用
- Riaz S, Emam S, Wang T, et al. Negative impact of comorbidities on all-cause mortality of patients with psoriasis is partially alleviated by biologic treatment: A real-world case-control study. J Am Acad Dermatol. 2024. PMID: 38387852. doi:10.1016/j.jaad.2024.01.078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。